<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297332</url>
  </required_header>
  <id_info>
    <org_study_id>I 82819</org_study_id>
    <secondary_id>NCI-2020-00697</secondary_id>
    <secondary_id>I 82819</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT04297332</nct_id>
  </id_info>
  <brief_title>Episodic Future Thinking and Future Thinking Priming for Smoking Cessation</brief_title>
  <official_title>Promising Methods to Decrease Delay Discounting and Reduce Relapse to Smoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the main and interactive effects of episodic future thinking and future
      thinking priming tasks on helping participants to quit smoking. Episodic future thinking and
      future thinking priming tasks may decrease delay discounting rates and reduce relapse to
      smoking and help participants quit smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To quantify the main and interactive effects of the episodic future thinking (EFT) and
      future thinking priming (FTP) tasks on delay discounting rate, latency to relapse, and
      multiple abstinence and self-regulation measures among smokers (n=76) who call a busy
      Quitline to quit smoking.

      OUTLINE: Participants are randomized to 1 of 4 arms.

      ARM I: Participants are provided with Forever Free relapse prevention booklets and receive a
      2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive
      coaching call within 24 hours of quit date. Beginning on the quit date, participants complete
      an active episodic future thinking or active future thinking priming task once per week for
      12 weeks, alternating every week between tasks.

      ARM II: Participants are provided with Forever Free relapse prevention booklets and receive a
      2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive
      coaching call within 24 hours of quit date. Beginning on the quit date, participants complete
      an active episodic future thinking or control future thinking priming task once per week for
      12 weeks, alternating every week between tasks.

      ARM III: Participants are provided with Forever Free relapse prevention booklets and receive
      a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive
      coaching call within 24 hours of quit date. Beginning on the quit date, participants complete
      a control episodic future thinking or active future thinking priming task once per week for
      12 weeks, alternating every week between tasks.

      ARM IV: Participants are provided with Forever Free relapse prevention booklets and receive a
      2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive
      coaching call within 24 hours of quit date. Beginning on the quit date, participants complete
      a control episodic future thinking or control future thinking priming tasks once per week for
      12 weeks, alternating every week between tasks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Anticipated">December 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Delay discounting rate</measure>
    <time_frame>Baseline, and 4 and 12 weeks after quit date</time_frame>
    <description>Assessed with the 5-Trial Adjusting Delay Discounting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Latency to relapse</measure>
    <time_frame>Baseline, assessed up to 12 weeks</time_frame>
    <description>Will be assessed with the Timeline Follow-Back procedure administered by telephone. Analyzed using generalized mixed models.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Latency to first relapse</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Defined as the number of days until first relapse (any smoking for seven consecutive days). Will be assessed with the Timeline Follow-Back procedure administered by telephone. Analyzed using generalized mixed models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days abstinent</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Will be evaluated by cox proportional-hazards survival model analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day point prevalence abstinence rates</measure>
    <time_frame>At 4 and 12 weeks after quit date</time_frame>
    <description>Will be evaluated by cox proportional-hazards survival model analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attentional, motor, and non-planning impulsiveness</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Assessed with the Barratt Impulsiveness Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral inhibition and behavioral activation</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Assessed with the Behavioral Avoidance/Inhibition scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-control</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Assessed with the Brief Self-Control Survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to regulate behavior to achieve goals</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Assessed with the Short Self-Regulation Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Tobacco-Related Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (active EFT, active FTP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (active EFT, control FTP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (control EFT, active FTP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (control EFT, control TFP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Complete active episodic thinking task</description>
    <arm_group_label>Arm I (active EFT, active FTP)</arm_group_label>
    <arm_group_label>Arm II (active EFT, control FTP)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>behavior modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>BEHAVIORAL THERAPY</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Complete active future thinking priming task</description>
    <arm_group_label>Arm I (active EFT, active FTP)</arm_group_label>
    <arm_group_label>Arm III (control EFT, active FTP)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>behavior modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>BEHAVIORAL THERAPY</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Complete control episodic future thinking task</description>
    <arm_group_label>Arm III (control EFT, active FTP)</arm_group_label>
    <arm_group_label>Arm IV (control EFT, control TFP)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>behavior modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>BEHAVIORAL THERAPY</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Complete control future thinking priming task</description>
    <arm_group_label>Arm II (active EFT, control FTP)</arm_group_label>
    <arm_group_label>Arm IV (control EFT, control TFP)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>behavior modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>BEHAVIORAL THERAPY</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Informational Intervention</intervention_name>
    <description>Provided with Forever Free relapse prevention booklet</description>
    <arm_group_label>Arm I (active EFT, active FTP)</arm_group_label>
    <arm_group_label>Arm II (active EFT, control FTP)</arm_group_label>
    <arm_group_label>Arm III (control EFT, active FTP)</arm_group_label>
    <arm_group_label>Arm IV (control EFT, control TFP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Replacement</intervention_name>
    <description>Receive nicotine patches, gum, or lozenges</description>
    <arm_group_label>Arm II (active EFT, control FTP)</arm_group_label>
    <arm_group_label>Arm III (control EFT, active FTP)</arm_group_label>
    <arm_group_label>Arm IV (control EFT, control TFP)</arm_group_label>
    <other_name>nicotine replacement therapy</other_name>
    <other_name>NRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone-Based Intervention</intervention_name>
    <description>Receive coaching call</description>
    <arm_group_label>Arm I (active EFT, active FTP)</arm_group_label>
    <arm_group_label>Arm II (active EFT, control FTP)</arm_group_label>
    <arm_group_label>Arm III (control EFT, active FTP)</arm_group_label>
    <arm_group_label>Arm IV (control EFT, control TFP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoke &gt;= 8 cigarettes daily

          -  Planning to quit in the next 14 days

          -  No regular use of other tobacco products

          -  Access to the internet

          -  In possession of a smartphone with text messaging capabilities

          -  In possession of an email address accessible at least every other day

        Exclusion Criteria:

          -  Unable or unwilling to provide consent

          -  Unable to provide data to the research team after the quit date

          -  Current use of bupropion or varenicline

          -  Drinking &gt;= 20 alcoholic drinks per week

          -  Use of drugs of abuse in the past 30 days

          -  Living in the same household as a participant already enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Sheffer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Sheffer</last_name>
      <phone>716-845-1186</phone>
      <email>Christine.Sheffer@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Christine Sheffer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

